Foamix Pharmaceuticals Ltd. (FOMX)
(Delayed Data from NSDQ)
$3.25 USD
+0.03 (0.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.24 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[FOMX]
Reports for Purchase
Showing records 1 - 20 ( 22 total )
Industry: Medical - Drugs
Manufacturing and Supply Agreement Established; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Daily Double Successfully Hit; FMX101 Approval and FMX103 Application Acceptance; Raising Target to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Industry: Medical - Drugs
Phase 2 Combo Product Candidate Study Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Awaiting FMX101 Regulatory Decision; Cash Replenished; Reiterate Buy and Reducing Target to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
1Q19 Financial Results Reported; Lead Candidates Nearing Regulatory Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
FMX101 New Drug Application Accepted for Review; Potential Approval in October 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
FY2018 Financial Results Reported; Looking Ahead to Regulatory Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
FMX101 Regulatory Submission Filed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Still Substantially Undervalued; Positive Pivotal FMX103 Data; Raising Target to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Additional Data From Third Confirmatory Pivotal FMX101 Trial Bolster Confidence; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
FMX101 Data Remains Solid; New Drug Application Next; Reducing Target to $11 Based on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
FMX101 Meets Endpoints in Third Phase 3 Trial; Regulatory Filing Soon; Raising Target to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
2Q18 Financial Results Reported; Spending Below Forecast; FMX101 Data Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Winlevi Pivotal Data Unlikely Cause for Concern; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
FMX103 Pivotal Trials Reach Last Patient Dosing Milestone; Top-Line Data in Early 4Q18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
1Q 2018 Financial Results Reported; Pivotal Trial Data Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Final Patient Dosed in Third Pivotal Trial of FMX101; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Cash Position Bolstered; Looking Ahead to Phase 3 Readouts
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
4Q and FY2017 Financial Results Reported; Looking Ahead to Clinical Data Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R